[go: up one dir, main page]

WO2006125819A3 - Forme medicamenteuse orale, microparticulaire, anti-mesusage - Google Patents

Forme medicamenteuse orale, microparticulaire, anti-mesusage Download PDF

Info

Publication number
WO2006125819A3
WO2006125819A3 PCT/EP2006/062623 EP2006062623W WO2006125819A3 WO 2006125819 A3 WO2006125819 A3 WO 2006125819A3 EP 2006062623 W EP2006062623 W EP 2006062623W WO 2006125819 A3 WO2006125819 A3 WO 2006125819A3
Authority
WO
WIPO (PCT)
Prior art keywords
analgesic
misuse
oral
analgesics
drugs
Prior art date
Application number
PCT/EP2006/062623
Other languages
English (en)
Other versions
WO2006125819A2 (fr
Inventor
Florence Guimberteau
Gerard Soula
Original Assignee
Flamel Tech Sa
Florence Guimberteau
Gerard Soula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Tech Sa, Florence Guimberteau, Gerard Soula filed Critical Flamel Tech Sa
Publication of WO2006125819A2 publication Critical patent/WO2006125819A2/fr
Publication of WO2006125819A3 publication Critical patent/WO2006125819A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

Le domaine de la présente invention est celui des médicaments oraux analgésiques, microparticulaires solides. L'invention est de fournir de nouveaux médicaments analgésiques permettant à la fois la prévention du mésusage et de l'addiction à certains analgésiques et/ou le contrôle de la variabilité de la concentration plasmatique et/ou la facilitation de l'administration orale ; et/ou l'association de analgésiques entre eux et/ou avec un ou plusieurs principes actifs dans une même forme orale. Le médicament selon l'invention comprend (i) des moyens anti-mésusage et une pluralité de microcapsules à libération modifiée d'analgésique(s), de diamètre moyen compris entre 50 et 600 µm, (ii) au moins 100 microcapsules par dose ; ce médicament pouvant être administré en une ou deux fois par jour à des fins analgésiques.
PCT/EP2006/062623 2005-05-24 2006-05-24 Forme medicamenteuse orale, microparticulaire, anti-mesusage WO2006125819A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0551344 2005-05-24
FR0551344A FR2889810A1 (fr) 2005-05-24 2005-05-24 Forme medicamenteuse orale, microparticulaire, anti-mesurage

Publications (2)

Publication Number Publication Date
WO2006125819A2 WO2006125819A2 (fr) 2006-11-30
WO2006125819A3 true WO2006125819A3 (fr) 2008-03-06

Family

ID=35414911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/062623 WO2006125819A2 (fr) 2005-05-24 2006-05-24 Forme medicamenteuse orale, microparticulaire, anti-mesusage

Country Status (3)

Country Link
US (1) US20070264326A1 (fr)
FR (1) FR2889810A1 (fr)
WO (1) WO2006125819A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024429A1 (fr) 2001-09-21 2003-03-27 Egalet A/S Systeme de liberation a base de polymere
EP1429744A1 (fr) 2001-09-21 2004-06-23 Egalet A/S Systeme a liberation de polymere de morphine
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2006133733A1 (fr) 2005-06-13 2006-12-21 Flamel Technologies Forme posologique orale comportant un systeme anti-abus
FR2892937B1 (fr) * 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
EP1810678A1 (fr) 2006-01-19 2007-07-25 Holger Lars Hermann Utilisation de morphine et naloxone pour la substitution de médicaments
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
CA2687192C (fr) 2007-06-04 2015-11-24 Egalet A/S Compositions pharmaceutiques a liberation controlee pour un effet prolonge
BRPI0821732A2 (pt) 2007-12-17 2015-06-16 Labopharm Inc Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
CN102316857A (zh) 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
WO2010089132A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Composition à libération immédiate résistant à une maltraitance par prise d'alcool
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
WO2011009604A1 (fr) 2009-07-22 2011-01-27 Grünenthal GmbH Forme galénique inviolable stabilisée à l’oxydation
US9877925B2 (en) 2010-05-14 2018-01-30 Ethypharm Alcohol-resistant oral pharmaceutical form
US20130059010A1 (en) * 2010-05-14 2013-03-07 Ethypharm Alcohol-resistant oral pharmaceutical form
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
HUE034711T2 (en) 2011-07-29 2018-02-28 Gruenenthal Gmbh Anti-Abuse, Immediate Release Tablet
RU2576456C2 (ru) * 2011-10-11 2016-03-10 Интерконтинентал Грейт Брендс Ллк Композиция инкапсулированного подсластителя, способ ее получения и содержащая ее жевательная резинка
CA2877183A1 (fr) 2012-07-06 2014-01-09 Egalet Ltd. Compositions pharmaceutiques de dissuasion d'abus a liberation controlee
US9737490B2 (en) * 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
CA2931553C (fr) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation de composition pharmaceutique en poudre par cryo-broyage
WO2017042325A1 (fr) 2015-09-10 2017-03-16 Grünenthal GmbH Protection contre un surdosage par voie orale à l'aide de formulations à libération immédiate dissuasives d'abus
WO2021138495A1 (fr) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particules pour administration multi-dose
CN113425683B (zh) * 2021-08-19 2022-09-20 谢彩华 一种三氮脒缓释注射剂及其制备方法

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
WO2003013479A1 (fr) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions et methodes destinees a prevenir l'abus d'opioides
WO2003013476A1 (fr) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions et procedes servant a empecher la surconsommation d'opioides
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
WO2003030878A2 (fr) * 2001-10-09 2003-04-17 Flamel Technologies Forme galenique orale microparticulaire
FR2837100A1 (fr) * 2002-03-18 2003-09-19 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
WO2003084518A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
WO2004004693A1 (fr) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Compositions pharmaceutiques empechant la consommation abusive d'opioides et d'autres drogues
WO2004010983A2 (fr) * 2002-07-26 2004-02-05 Flamel Technologies Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
WO2004026262A2 (fr) * 2002-09-23 2004-04-01 Verion, Inc. Compositions pharmaceutiques n'induisant pas l'abus
WO2004037259A1 (fr) * 2002-10-25 2004-05-06 Grünenthal GmbH Forme galenique protegee contre un usage detourne
US20040092542A1 (en) * 2000-02-08 2004-05-13 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
WO2004100894A2 (fr) * 2003-05-12 2004-11-25 Shire Laboratories, Inc. Formulations de medicament presentant un potentiel d'abus reduit
WO2005016313A1 (fr) * 2003-08-06 2005-02-24 Grünenthal GmbH Forme de preparation securisee contre un emploi abusif
WO2005016314A1 (fr) * 2003-08-06 2005-02-24 Grünenthal GmbH Forme galenique empechant un usage detourne
WO2005063214A1 (fr) * 2003-12-24 2005-07-14 Grünenthal GmbH Procede de fabrication d'une forme d'administration securisee contre tout usage detourne

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
IL103224A (en) * 1992-09-18 1998-08-16 Teva Pharma Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3
IL136805A0 (en) * 1997-12-22 2001-11-25 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
DE602005010899D1 (de) * 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US20040092542A1 (en) * 2000-02-08 2004-05-13 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
WO2003013479A1 (fr) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions et methodes destinees a prevenir l'abus d'opioides
WO2003013476A1 (fr) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Compositions et procedes servant a empecher la surconsommation d'opioides
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
WO2003030878A2 (fr) * 2001-10-09 2003-04-17 Flamel Technologies Forme galenique orale microparticulaire
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
FR2837100A1 (fr) * 2002-03-18 2003-09-19 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
WO2003084518A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
WO2004004693A1 (fr) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Compositions pharmaceutiques empechant la consommation abusive d'opioides et d'autres drogues
WO2004010983A2 (fr) * 2002-07-26 2004-02-05 Flamel Technologies Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
WO2004026262A2 (fr) * 2002-09-23 2004-04-01 Verion, Inc. Compositions pharmaceutiques n'induisant pas l'abus
WO2004037259A1 (fr) * 2002-10-25 2004-05-06 Grünenthal GmbH Forme galenique protegee contre un usage detourne
WO2004100894A2 (fr) * 2003-05-12 2004-11-25 Shire Laboratories, Inc. Formulations de medicament presentant un potentiel d'abus reduit
WO2005016313A1 (fr) * 2003-08-06 2005-02-24 Grünenthal GmbH Forme de preparation securisee contre un emploi abusif
WO2005016314A1 (fr) * 2003-08-06 2005-02-24 Grünenthal GmbH Forme galenique empechant un usage detourne
WO2005063214A1 (fr) * 2003-12-24 2005-07-14 Grünenthal GmbH Procede de fabrication d'une forme d'administration securisee contre tout usage detourne

Also Published As

Publication number Publication date
WO2006125819A2 (fr) 2006-11-30
US20070264326A1 (en) 2007-11-15
FR2889810A1 (fr) 2007-02-23

Similar Documents

Publication Publication Date Title
WO2006125819A3 (fr) Forme medicamenteuse orale, microparticulaire, anti-mesusage
WO2008064192A3 (fr) Suspensions analgésiques à libération modifiée
WO2008157103A3 (fr) Formes de dosage solides ou semi-solides à libération modifiée
CA2494234A1 (fr) Techniques et formes de dose d'apport commande de paliperidone
WO2007013975A3 (fr) Compositions et procedes destines a controler l'abus de medicaments
WO2008060964A3 (fr) Procédés d'administration de médications pour la perte de poids
WO2006113505A3 (fr) Systemes d'apport de substances pharmaceutiques destines a des medicaments hydrophobes et compositions comprenant ces derniers
WO2006089843A3 (fr) Forme medicamenteuse orale microparticulaire anti-mesusage
WO2006022996A3 (fr) Forme posologique contenant des medicaments multiples
MXPA02007762A (es) Sistema de suministro de farmaco pulsativos temporalizados.
WO2004112756A8 (fr) Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
WO2004024209A3 (fr) Materiaux et procedes d'administration et d'absorption de medicaments
WO2007143155A3 (fr) Forme pharmaceutique à liberation prolongée contenant de la phényléphrine
WO2001019337A3 (fr) Formes et procedes pharmaceutiques permettant une therapie par la reboxetine efficace avec une seule administration quotidienne
WO2005032567A3 (fr) Methode
WO2001052823A3 (fr) Compositions et methodes permettant d'elaborer un profil de liberation dans l'administration transdermique d'agents actifs
WO2006039022A3 (fr) Administration orale regionale controlee
WO2007048223A3 (fr) Systeme d'administration de medicaments a retention gastrique
WO2006063189A3 (fr) Systeme d'administration de medicament a desintegration rapide
WO2007012019A3 (fr) Medicaments contenant famotidine et ibuprofene, et administration desdits medicaments
WO2007009806A3 (fr) Formulations posologiques solides de medicaments narcotiques presentant une adsorption buccale amelioree
WO2004064815A8 (fr) Formulation de dosage oral
WO2008142572A3 (fr) Formulation de comprimé à libération contrôlée contenant de l'aluminométasilicate de magnésium
PT1411921E (pt) Composições farmacêuticas contendo terbinafina e suas utilizações
DE60225481D1 (de) Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06777242

Country of ref document: EP

Kind code of ref document: A2